risk of bleeding requiring blood transfusion and re-operation 1 . In on-pump cardiac surgery, the use of cardiopulmonary bypass may activate systemic to the increased risk of postoperative bleeding requiring transfusion and surgical re-exploration. One of many approaches to reduce perioperative bleeding and transfusion in cardiac surgery is the pulmonary bypass. According to the latest practice guidelines for perioperative blood transfusion and adjuvant therapies by the American Society of useful in reducing allogeneic blood transfusion for patients at high risk of excessive bleeding 2 . Recent systematic reviews suggested that aprotinin, a serine protease inhibitor derived from bovine lungs, is than lysine analogues in reducing perioperative transfusion and re-operation 1,3 .
The use of aprotinin in cardiac surgery has been called into question recently when a large observational study suggested that the use of aprotinin in cardiac surgery may increase the risk of acute renal failure 4 . The results of this study were, however, not substantiated by some other observational studies [5] [6] [7] . Aprotinin was commonly used in many cardiothoracic units in Australia until the manufacturer of aprotinin (Bayer AG) temporarily suspended the marketing of the drug very recently because of a concern about its safety Australian cardiothoracic units are sparse 8 . We aim in this study to assess the effects of aprotinin on the risk of acute renal failure requiring dialysis. This retrospective cohort study utilised the clinical databases of the intensive care unit (ICU) and cardiothoracic operating theatre of Royal Perth Hospital in Western Australia. All data were collected prospectively and subsequently retrieved from the ICU and operating theatre databases. The study was deemed to be a "Clinical Audit" by the human research ethics committee approval was waived.
All on-pump cardiac surgical patients between included except those who died in the operating theatre and those who were dialysis-dependent before their cardiac surgery. The usual practice of this cardiothoracic unit was to cease aspirin or other elective surgery, unless there was a strong medical indication to continue the drug. The use of blood products including red blood cells, platelets and fresh frozen plasma was selective and determined by the blood test results and clinical condition of the patient. The use of aprotinin was also selective and the dose was determined by the duty cardiothoracic anaesthestists.
The outcomes analysed in this study included intraoperative and postoperative transfusion requirements, bleeding requiring surgical reexploration, maximum postoperative creatinine concentrations, maximum postoperative renal Sequential Organ Failure Assessment (SOFA) score 9 , the requirement for acute renal replacement therapy, occurrence of postoperative atrial ICU and hospital stay and hospital mortality. No patients were lost to follow-up or had missing mortality and renal failure data.
The clinical predictors of acute renal failure considered included patient's age, gender, co-morbidities such as diabetes mellitus and hypertension, preoperative serum creatinine concentrations, whether it was a re-do cardiac surgery, coronary artery bypass graft alone or with valve surgery, cardiopulmonary bypass time, aorta cross-clamp time, the status of the left ventricular function before surgery, urgency of the cardiac surgery, the total amount of allogeneic blood transfusion and the use of aprotinin during cardiopulmonary bypass. In this study, emergency required within a few days.
In the univariable analyses, continuous variables were analysed by t-tests, categorical variables and continuous variables with skewed distributions were analysed by chi-square tests and Mann-Whitney tests, respectively. The association between the potential clinical predictors of renal failure after cardiac surgery and postoperative renal failure requiring renal replacement therapy was analysed by multivariate logistic regression analyses. In the multivariate analyses, variables were removed in a stepwise manner if the P value was more than 0.25 during the multivariate modelling process, starting from the variable with the highest P value. The variables associated with a P value <0.25. In this study a P value <0.05 was regarded as statistically with SPSS for Windows (version 13.0, SPSS Inc., 2005, IL, U.S.A.). (65) Mildly impaired 50 (16) 13 (12) Moderately impaired 31 (10) 17 (16) Severely impaired 54 (17) Among a total of 423 consecutive on-pump cardiac surgical patients between January 1, 2005 and during their surgery. The mean dose of aprotinin used was 3.3 million KIU (median 3.0 million KIU, standard deviation: 2.8 million KIU, interquartile range: 2 million KIU to 4 million KIU). The patients who received aprotinin had a shorter period of time between the cessation of aspirin and surgery, were more likely to have impaired left ventricular function, urgent or emergency cardiac surgery, both coronary artery bypass graft and heart valve surgery performed and a longer period of bypass and aortic cross-clamp time ( Table 1) .
As expected from the shorter period from cessation of aspirin, more complicated surgery and a longer bypass time associated with the aprotinin group, these patients received more intraoperative transfusion of red blood cells, fresh frozen plasma and platelets. Postoperatively, the aprotinin group received slightly fewer blood transfusions but the total blood transfusions including both the intraoperative and postoperative period was not (Table 2) . Although the aprotinin group was associated with a slightly higher maximum renal SOFA score postoperatively, the incidence of acute renal failure requiring renal replacement therapy analysis ( Table 2) . Apart from a longer length of hospital stay, the use of aprotinin was also not associated with an increased risk of other postoperative complications including surgical cerebrovascular accident and hospital mortality.
In the multivariate analysis, only preoperative creatinine concentrations (odds ratio [OR] 1.07 for every 10 μmol/l increment in preoperative P=0.027), age (OR 1.12 for every year increase in age, 95% CI 1.02 to 1.22, P=0.013), total amount of allogeneic blood transfusion (OR 1.27 for every unit of red cells transfusion, 95% CI 1.08 to 1.50, P=0.003) factors for acute renal failure requiring renal replacement therapy. The use of aprotinin was not associated with a higher risk of acute renal failure requiring renal replacement therapy (OR 0.27, 95% CI 0.06 to 1.20, P=0.085), after adjusting for other risk factors of acute renal failure (Table 3 ).
This study showed that the major risk factors for acute renal failure after on-pump cardiac surgery were preoperative renal function, age, amount of allogeneic transfusion and the urgency of surgery. Aprotinin was commonly used in our patients who underwent complicated cardiac surgery and those who were at high risk of bleeding. The use of aprotinin did not appear to increase the risk of acute renal failure requiring dialysis.
Aprotinin is metabolised by lysosomal enzymes tubule of nephrons and can increase serum creatinine concentrations transiently 10-12 . A slight increase in the renal SOFA score and maximum postoperative serum creatinine concentrations after the use of aprotinin in our patients was consistent with the results of these earlier clinical studies. A recent observational study suggested that aprotinin might have a dose-dependent effect on the risk of acute renal failure in cardiac surgery 4 . This study was, however, limited by a number of methodological problems 13 entirely substantiated by many other observational studies and systematic reviews 1,3,5-7 . A recent metaanalysis showed that only the use of high-dose aprotinin (>4 million KIU plus maintenance 0.5 million KIU/h during bypass) was associated with an increased risk of acute renal dysfunction concentration >44 μmol/l) (relative risk 1.47 for high-dose vs. 1.01 for low-dose regimen: 2 million KIU plus 0.25 million KIU/h maintenance during bypass) but not acute renal failure requiring dialysis when compared with placebo 3 albeit limited, consistent with the results of this meta-analysis in that the relatively low-doses of an increased risk of acute renal failure requiring dialysis, after adjusting for other risk factors of acute renal failure 3, [5] [6] [7] . We are aware that the dosedependent renal toxicity of aprotinin in cardiac surgery remains controversial 13 and high-doses of aprotinin have also been reported to cause acute renal failure after spinal surgery 14 . Whether the use of an ultra-low dose of aprotinin (1 million KIU) or even topical application of aprotinin can result without the risk of causing acute renal impairment remains uncertain but merits further investigation by large randomised controlled studies 13, 15, 16 .
studies that pre-existing renal impairment, total amount of blood transfusion and non-elective cardiac surgery are the major risk factors for acute renal failure requiring dialysis 13,17 . We could not, renal failure after cardiac surgery such as diabetes mellitus, ejection fraction less than or equal to 40%, previous cardiac surgery and procedure other than coronary artery bypass grafting in this study. This is most likely due to the small sample size of our cohort and the low incidence of acute renal failure requiring dialysis.
observational studies are prone to bias. Selection bias, as evidenced by the selected use of aprotinin in the sicker group of cardiac patients in this study, may not be fully adjusted for in an observational study. Second, the sample size of this cohort was small (n=423) and the incidence of renal failure requiring dialysis was low (2.8%). This reduced the power of the study to detect the potential effect of aprotinin on the risk of acute renal failure requiring dialysis. Furthermore, the clinical decision to initiate renal replacement therapy will depend on many factors including acidosis, hyperkalaemia and pulmonary oedema that are not considered in this study. Finally this was a single-centre study including only adult cardiac surgical patients treated with relatively small doses of aprotinin, and hence our results are not generalisable to paediatric cardiac surgery or when larger doses of aprotinin are used 18 .
In summary, the use of a relatively small dose of aprotinin in patients who were at high risk of bleeding did not increase the risk of acute renal failure requiring dialysis, after adjusting for other risk factors for acute renal failure. The relevance of our results will depend on whether the effectiveness and safety of a lower dose of aprotinin can be different perioperative settings. 
